作者
Simona Soverini, Sabrina Colarossi, Alessandra Gnani, Gianantonio Rosti, Fausto Castagnetti, Angela Poerio, Ilaria Iacobucci, Marilina Amabile, Elisabetta Abruzzese, Ester Orlandi, Franca Radaelli, Fabrizio Ciccone, Mario Tiribelli, Roberto di Lorenzo, Clementina Caracciolo, Barbara Izzo, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, Giovanni Martinelli, GIMEMA Working Party on Chronic Myeloid Leukemia
发表日期
2006/12/15
期刊
Clinical Cancer Research
卷号
12
期号
24
页码范围
7374-7379
出版商
American Association for Cancer Research
简介
Purpose: ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients.
Experimental Design: Using denaturing high-performance liquid chromatography and sequencing, we screened for ABL kinase domain mutations in 370 Ph+ patients with evidence of hematologic or cytogenetic resistance to imatinib.
Results: Mutations were found in 127 of 297 (43%) evaluable patients. Mutations were found in 27% of chronic-phase patients (14% treated with imatinib frontline; 31% treated with imatinib post-IFN failure), 52% of accelerated-phase patients, 75% of myeloid blast crisis patients, and 83% of lymphoid blast crisis/Ph+ acute lymphoblastic leukemia (ALL) patients. Mutations were associated in 30% of patients with primary resistance (44% hematologic and 28% cytogenetic) and in 57 …
引用总数
学术搜索中的文章
S Soverini, S Colarossi, A Gnani, G Rosti, F Castagnetti… - Clinical Cancer Research, 2006